Searched for
GENERIC SEMAGLUTIDE
Sandoz bets big on biosimilars, aims to double group sales by 2035Sandoz plans to more than double annual net sales by 2035, with biosimilars leading growth. The company will expand its biosimilar portfoli...- How PGIM India's Rs 112 crore Healthcare Fund picks CDMO stocks to generate alphaPGIM India Healthcare Fund generated a 22% return over the past year by over-allocating to high-growth segments like CDMO, specialty pharma...
- Elara initiates coverage on Alkem, Eris, IPCA and Mankind. Check ratings and targetsElara has initiated coverage on four pharmaceutical stocks, assigning Buy, Accumulate and Reduce ratings. Alkem Laboratories emerged as its...
- Widening waistline: India's big, fat obesity hotspots may not be just the biggest cities anymoreIndia sees a significant rise in overweight and obese populations recently. Rural areas show a particularly sharp increase in these health ...
- MOFSL stays bullish on Sun Pharma; sees 16% upside on innovation pipelineSun Pharma's June quarter results met analyst expectations, signaling future growth. The company is expanding its specialty and innovative ...
- Losing weight fast on GLP-1 drugs? Your hair could be the next thing to goDermatologists report increased hair loss among GLP-1 drug users experiencing rapid weight reduction. This side effect, often telogen efflu...
- GLP-1 demand stirs up hunger for obesity care talentDemand for nutrition professionals is rapidly rising across India. Hospitals and digital health platforms are hiring more dietitians and ed...
- Sun Pharma Q1 Results: Profit rises 27% YoY to Rs 2,895 crore; revenue climbs 10.5%Sun Pharma Q1 Results: Sun Pharma reported a 27% YoY rise in Q1 net profit to Rs 2,895 crore, while revenue grew 10% to Rs 15,300 crore, dr...
- As we look to the next decade, I hope in the future we can further grow in generics as we transition into drug innovation: Aman Mehta, MD, Torrent PharmaceuticalsTorrent Pharma aims to become a top three Indian drug maker. The company is transitioning from generics to drug innovation for growth. Aman...
- US market drag keeps Dr Reddy's, Cipla under pressure despite strong product pipelineIndian pharmaceutical firms experienced a challenging June quarter, marked by declining US business profits. Dr Reddy's and Cipla saw signi...
- Stocks in news: Infosys, Cipla, Meesho, Suzlon Energy, IndiGo, NTPCMarkets extended their losing streak for a fourth consecutive session. Infosys reported a 12% year-on-year profit growth in its first quart...
- Cipla in no hurry to launch semaglutide as Yurpeak gains tractionCipla is focusing on its tirzepatide brand Yurpeak in India's obesity market. Yurpeak has become the second largest GLP-1 product since its...
- Dr Reddy’s shares crack 9% after weak Q1; these 3 brokerages slash their target pricesDr Reddy’s shares plunged 9% on Thursday after the drugmaker reported a weak Q1 FY27 performance, with net profit tumbling 69% year-on-year...
- Dr Reddy’s aims to resume semaglutide supply by November after API fixDr Reddy's expects to resume semaglutide supplies by November after resolving quality issues. The company identified the root cause and pla...
- Domestic formulations, chronic therapies to drive Pharma Q1; US generics remain dragThe healthcare sector anticipates strong growth in domestic formulations and emerging markets. Companies with less US generics dependence w...
- Novo Nordisk's obesity drug Wegovy wins India approval to fight silent fatty liver killerIndia's drug regulator approved Novo Nordisk's Wegovy for MASH treatment. This drug targets a serious progressive form of fatty liver disea...
- Sun Pharma gets SAHPRA approval for generic semaglutide injection in South Africa for type 2 diabetesSouth Africa's regulator approved Sun Pharma's generic semaglutide injection for diabetes. This approval allows marketing to supplement die...
- Dr Reddy’s pauses weight loss drug on quality fearsDr Reddy's Laboratories will halt semaglutide injection supplies until at least October. Unspecified impurities were identified during the ...
- Dr Reddy's shares slide 7% after delay in semaglutide supplies over quality concernsDr Reddy's shares fell sharply on Thursday after the company delayed commercial supplies of its semaglutide product due to a quality issue ...
- Wegovy, Ozempic regain weight as Indian generics fall behindNovo Nordisk's weight-loss drugs are regaining market share from Indian generics. Innovator brands show steady month-on-month sales growth,...
Load More
